Amgen Forced To Suspend Trial Of Promising Cancer Drug
November 20, 2008
Washington (dbTechno) - Amgen Inc., a unit of Takeda Pharmaceutical Co. has been forced to suspend a late-stage trial of a very promising cancer drug.
The experimental drug in question is known as motesanib and was going to be used in combination with other drugs as something that could treat lung cancer.
The other drugs it was designed to work along with include carboplatin, as well as paclitaxel.
Data has shown that those who take the new experimental drug experience higher early mortality rates.
This compared directly to patients who were not on the drug and instead were taking a placebo.
Amgen has immediately pulled the plug and suspended the trial.
Breaking News
Sandra Bullock Not Attending London Movie PremierBoston (DbTechNo) - It is being reported that actress Sandra Bullock will not be attending the London premiere of The Blind...
Environmental Protection Agency Reviewing Fle and Tick Product LabellingThe Environmental Protection Agency (EPA) will be taking a closer look at flea and tick products for dogs and cats after...
American Idol Wannabes Take to the StageAmerican Idol featured performances by the top 12 contestants last night, all of whom sang a song from the Rolling Stones. As...









Comments
All comments are moderated.
If your comment is approved, it will be posted within 24 hours